Loading company…
Timberlyne Therapeutics develops therapies for autoimmune diseases, including a CD38-targeting antibody.
Timberlyne Therapeutics is developing CM313, an IgG1 monoclonal antibody targeting CD38, for conditions including immune thrombocytopenia and systemic lupus erythematosus. The clinical-stage company was founded in 2024 and is based in San Diego, US. In January 2025, it raised USD 180 million in Series A funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in